Logo image of RLAY

RELAY THERAPEUTICS INC (RLAY) Stock Fundamental Analysis

USA - NASDAQ:RLAY - US75943R1023 - Common Stock

6.86 USD
-0.08 (-1.15%)
Last: 11/4/2025, 7:05:22 PM
6.79 USD
-0.07 (-1.02%)
After Hours: 11/4/2025, 7:05:22 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to RLAY. RLAY was compared to 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RLAY as it has an excellent financial health rating, but there are worries on the profitability. RLAY is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RLAY has reported negative net income.
In the past year RLAY has reported a negative cash flow from operations.
RLAY had negative earnings in each of the past 5 years.
RLAY had a negative operating cash flow in each of the past 5 years.
RLAY Yearly Net Income VS EBIT VS OCF VS FCFRLAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -42.75%, RLAY perfoms like the industry average, outperforming 56.18% of the companies in the same industry.
Looking at the Return On Equity, with a value of -46.80%, RLAY is in the better half of the industry, outperforming 67.42% of the companies in the same industry.
Industry RankSector Rank
ROA -42.75%
ROE -46.8%
ROIC N/A
ROA(3y)-35.23%
ROA(5y)-34.11%
ROE(3y)-39.82%
ROE(5y)-38.03%
ROIC(3y)N/A
ROIC(5y)N/A
RLAY Yearly ROA, ROE, ROICRLAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

RLAY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLAY Yearly Profit, Operating, Gross MarginsRLAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

8

2. Health

2.1 Basic Checks

RLAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
RLAY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RLAY has been increased compared to 5 years ago.
RLAY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RLAY Yearly Shares OutstandingRLAY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RLAY Yearly Total Debt VS Total AssetsRLAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 7.27 indicates that RLAY is not in any danger for bankruptcy at the moment.
RLAY has a Altman-Z score of 7.27. This is in the better half of the industry: RLAY outperforms 79.03% of its industry peers.
There is no outstanding debt for RLAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.27
ROIC/WACCN/A
WACC8.77%
RLAY Yearly LT Debt VS Equity VS FCFRLAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 20.92 indicates that RLAY has no problem at all paying its short term obligations.
RLAY has a Current ratio of 20.92. This is amongst the best in the industry. RLAY outperforms 95.13% of its industry peers.
RLAY has a Quick Ratio of 20.92. This indicates that RLAY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 20.92, RLAY belongs to the top of the industry, outperforming 95.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 20.92
Quick Ratio 20.92
RLAY Yearly Current Assets VS Current LiabilitesRLAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

RLAY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.62%, which is quite impressive.
RLAY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.25%.
Measured over the past years, RLAY shows a very strong growth in Revenue. The Revenue has been growing by 48.92% on average per year.
EPS 1Y (TTM)22.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.58%
Revenue 1Y (TTM)-86.25%
Revenue growth 3Y48.92%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 7.00% on average over the next years.
Based on estimates for the next years, RLAY will show a very strong growth in Revenue. The Revenue will grow by 45.30% on average per year.
EPS Next Y27.56%
EPS Next 2Y12.64%
EPS Next 3Y5.25%
EPS Next 5Y7%
Revenue Next Year-19.63%
Revenue Next 2Y-7.08%
Revenue Next 3Y25.93%
Revenue Next 5Y45.3%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
RLAY Yearly Revenue VS EstimatesRLAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
RLAY Yearly EPS VS EstimatesRLAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RLAY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RLAY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLAY Price Earnings VS Forward Price EarningsRLAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLAY Per share dataRLAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.64%
EPS Next 3Y5.25%

More info and screens

0

5. Dividend

5.1 Amount

RLAY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RELAY THERAPEUTICS INC

NASDAQ:RLAY (11/4/2025, 7:05:22 PM)

After market: 6.79 -0.07 (-1.02%)

6.86

-0.08 (-1.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06/amc
Inst Owners83.06%
Inst Owner Change-1.24%
Ins Owners1.42%
Ins Owner Change-1.48%
Market Cap1.18B
Revenue(TTM)8.36M
Net Income(TTM)-311549000
Analysts84.44
Price Target13.87 (102.19%)
Short Float %15.58%
Short Ratio14.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.91%
Min EPS beat(2)7.59%
Max EPS beat(2)18.23%
EPS beat(4)4
Avg EPS beat(4)16.7%
Min EPS beat(4)7.59%
Max EPS beat(4)21.46%
EPS beat(8)8
Avg EPS beat(8)16.79%
EPS beat(12)10
Avg EPS beat(12)11.88%
EPS beat(16)11
Avg EPS beat(16)8.44%
Revenue beat(2)2
Avg Revenue beat(2)38095.3%
Min Revenue beat(2)1006.21%
Max Revenue beat(2)75184.3%
Revenue beat(4)2
Avg Revenue beat(4)18997.6%
Min Revenue beat(4)-100%
Max Revenue beat(4)75184.3%
Revenue beat(8)4
Avg Revenue beat(8)11864%
Revenue beat(12)5
Avg Revenue beat(12)7889.53%
Revenue beat(16)7
Avg Revenue beat(16)5947.99%
PT rev (1m)2.86%
PT rev (3m)-6.21%
EPS NQ rev (1m)1.51%
EPS NQ rev (3m)12.52%
EPS NY rev (1m)1.01%
EPS NY rev (3m)9.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)265.72%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)8.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 141.54
P/FCF N/A
P/OCF N/A
P/B 1.78
P/tB 1.78
EV/EBITDA N/A
EPS(TTM)-1.95
EYN/A
EPS(NY)-1.75
Fwd EYN/A
FCF(TTM)-1.52
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS0.05
BVpS3.86
TBVpS3.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.75%
ROE -46.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.23%
ROA(5y)-34.11%
ROE(3y)-39.82%
ROE(5y)-38.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.97%
Cap/Sales 7.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.92
Quick Ratio 20.92
Altman-Z 7.27
F-Score4
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)111.54%
Cap/Depr(5y)95.45%
Cap/Sales(3y)230.95%
Cap/Sales(5y)161.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.58%
EPS Next Y27.56%
EPS Next 2Y12.64%
EPS Next 3Y5.25%
EPS Next 5Y7%
Revenue 1Y (TTM)-86.25%
Revenue growth 3Y48.92%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-19.63%
Revenue Next 2Y-7.08%
Revenue Next 3Y25.93%
Revenue Next 5Y45.3%
EBIT growth 1Y46.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.67%
EBIT Next 3Y5.71%
EBIT Next 5Y10.71%
FCF growth 1Y1.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.95%
OCF growth 3YN/A
OCF growth 5YN/A

RELAY THERAPEUTICS INC / RLAY FAQ

Can you provide the ChartMill fundamental rating for RELAY THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 4 / 10 to RLAY.


Can you provide the valuation status for RELAY THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to RELAY THERAPEUTICS INC (RLAY). This can be considered as Overvalued.


What is the profitability of RLAY stock?

RELAY THERAPEUTICS INC (RLAY) has a profitability rating of 1 / 10.